Narendranath Epperla

Narendranath Epperla's research focuses on lymphoma, a type of blood cancer, with particular attention to how patients respond to newer treatments such as CAR T-cell therapy (a treatment that reprograms a patient's own immune cells to attack cancer) and bispecific antibodies (lab-made proteins that direct immune cells toward cancer cells). Much of the work uses large, real-world, multi-center patient data sets to study outcomes for aggressive and relapsed/refractory forms of lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, and Hodgkin lymphoma. This is clinical/translational research aimed at understanding how existing and emerging therapies perform outside of controlled clinical trials.

Publication output was relatively steady from 2017-2022 (around 20-35 papers/year) before roughly doubling from 2023 onward, indicating a recent sharp increase in research activity.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026